Testimony Before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee Regarding Donanemab for the Treatment of Alzheimer’s Disease
In testimony before the Food and Drug Administration’s (FDA’s) Peripheral and Central Nervous System Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve donanemab for the treatment of Alzheimer’s Disease because the evidence for the drug’s benefits does not outweigh its significant risks.